27 November 2020 : Clinical Research
The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
Lijun Hu1ABCDEF*, Ze Kong1BCDF, Qinghong Meng1BCD, Jianlin Wang1BCF, Mengyun Zhou1BC, Jingping Yu1ACEG, Xiaodong Jiang2ACEGDOI: 10.12659/MSM.927221
Med Sci Monit 2020; 26:e927221
Table 1 Baseline characteristics of study participants.
| Apatinib group (n=31) | CCRT group (n=34) | P | |
|---|---|---|---|
| Male (%) | 21 (77.4%) | 24 (73.5%) | 0.716 |
| Age (years) | 70.5±6.7 | 69.5±8.2 | 0.516 |
| Hypertension (%) | 15 (48.4%) | 12 (35.3%) | 0.285 |
| Diabetes (%) | 3 (10.0%) | 3 (8.8%) | 0.872 |
| Tumor location | 0.389 | ||
| Neck, upper thoracic part | 11 (35.5%) | 7 (20.6%) | |
| Middle thoracic part | 14 (45.2%) | 20 (58.8%) | |
| Lower thoracic part | 6 (19.4%) | 7 (20.6%) | |
| Tumor type | 0.618 | ||
| Medullary type | 23 (74.2%) | 27 (79.4%) | |
| Ulcerative type, constrictive type | 8 (25.8%) | 7 (20.6%) | |
| T staging | 0.509 | ||
| T | 15 (48.4%) | 12 (35.3%) | |
| T | 9 (29.0%) | 14 (41.2%) | |
| T | 7 (22.6%) | 8 (23.5%) | |
| N staging | 0.643 | ||
| N | 1 (3.2%) | 2 (5.9%) | |
| N | 15 (48.4%) | 19 (55.9%) | |
| N | 15 (48.4%) | 13 (38.2%) | |
| TNM staging | 0.571 | ||
| Stage II | 14 (45.2%) | 13 (38.2%) | |
| Stage III | 17 (54.8%) | 21 (61.8%) | |
| CEA | 2.7 (1.5, 4.0) | 2.7 (1.9, 3.9) | 0.927 |
| SCC | 1.5 (0.8, 2.5) | 1.8 (1.2, 3.5) | 0.184 |
| Radiotherapy dose (Gy) | 56.3±5.8 | 57.5±5.4 | 0.405 |
| Apatinib group – chemoradiotherapy plus Apatinib group; CCRT group – concurrent chemoradiotherapy only group; CEA – carcinoembryonic antigen; SCC – squamous cell carcinoma antigen. | |||